EORTC (European Organisation for Research and Treatment of Cancer) shared a post on LinkedIn:
”We’re thrilled to announce the results of the TOPGEAR trial on gastric and gastroesophageal junction adenocarcinoma.
The study showed that the addition of preoperative chemoradiotherapy did not improve progression-free survival or overall survival compared to perioperative chemotherapy alone.
This breakthrough will impact clinical practice worldwide.
Source: EORTC/LinkedIn